ADITXT INC (ADTX) Stock News

USA - NASDAQ:ADTX - US0070258027 - Common Stock

0.7522 USD

-0.07 (-8.77%)

Last: 9/30/2025, 7:30:07 PM

0.77 USD

+0.02 (+2.37%)

After Hours: 9/30/2025, 7:30:07 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADTX Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Benzinga - Mentions: MBRX ADAP LYRA ALXO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

19 days ago - By: Evofem Biosciences, Inc.

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

a month ago - By: Aditxt, Inc.

Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

a month ago - By: Evofem Biosciences, Inc.

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

a month ago - By: Benzinga - Mentions: SNGX VKTX PPCB XFOR ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Evofem Biosciences, Inc.

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

2 months ago - By: Evofem Biosciences, Inc.

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

2 months ago - By: Aditxt, Inc.

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

2 months ago - By: Evofem Biosciences, Inc.

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

2 months ago - By: Aditxt, Inc.

Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

2 months ago - By: Aditxt, Inc.

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

2 months ago - By: Aditxt, Inc.

Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

3 months ago - By: Evofem Biosciences, Inc.

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

3 months ago - By: Aditxt, Inc.

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

3 months ago - By: Aditxt, Inc.

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

4 months ago - By: Evofem Biosciences, Inc.

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

4 months ago - By: Aditxt, Inc.

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

4 months ago - By: Aditxt, Inc.

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

4 months ago - By: Aditxt, Inc.

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

5 months ago - By: Aditxt, Inc.

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

6 months ago - By: Business Wire

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

6 months ago - By: Business Wire

KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

6 months ago - By: Aditxt, Inc.

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

6 months ago - By: Aditxt, Inc.

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

6 months ago - By: Yahoo Finance - Mentions: TSLA

Why Aditxt Inc. (ADTX) Went Down On Thursday?

6 months ago - By: Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

6 months ago - By: Aditxt, Inc.

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

6 months ago - By: Aditxt, Inc.

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

6 months ago - By: Evofem Biosciences, Inc. - Mentions: EVFM

Evofem Reports Fourth Consecutive Year of Net Sales Growth

6 months ago - By: Aditxt, Inc.

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk